Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals
- PMID: 24105030
- PMCID: PMC4164055
- DOI: 10.1097/QAD.0000000000000078
Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals
Abstract
Objectives: To compare the proportion, timing and hazards of non-AIDS death and AIDS death among men and women who initiated HAART at different CD4 cell counts to mortality risks of HIV-uninfected persons with similar risk factors.
Design: Prospective cohort studies.
Methods: We used parametric mixture models to compare proportions of AIDS and non-AIDS mortality and ages at death, and multivariable Cox models to compare cause-specific hazards of mortality, across levels of CD4 cell count at HAART initiation (≤200 cells/μl: 'late', 201-350 cells/μl: 'intermediate', >350 cells/μl: 'early') and with HIV-uninfected individuals from the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. We used multiple imputation methods to address lead-time bias in sensitivity analysis.
Results: Earlier initiators were more likely to die of non-AIDS causes (early: 78%, intermediate: 74%, late: 49%), and at older ages (median years 72, 69, 66), relative to later initiators. Estimated median ages at non-AIDS death for each CD4 cell count category were lower than that estimated for the HIV-uninfected group (75 years). In multivariable analysis, non-AIDS death hazard ratios relative to early initiators were 2.15 for late initiators (P < 0.01) and 1.66 for intermediate initiators (P = 0.01); AIDS death hazard ratios were 3.26 for late initiators (P < 0.01) and 1.20 for intermediate initiators (P = 0.28). Strikingly, the adjusted hazards for non-AIDS death among HIV-uninfected individuals and early initiators were nearly identical (hazard ratio 1.01). Inferences were unchanged after adjustment for lead-time bias.
Conclusion: Results suggest the possibility of reducing the risk of non-AIDS mortality among HIV-infected individuals to approximate that faced by comparable HIV-uninfected individuals.
Conflict of interest statement
There are no conflicts of interest.
Figures
Comment in
-
Beneficial impact of antiretroviral therapy on non-AIDS mortality.AIDS. 2014 Jan 14;28(2):273-4. doi: 10.1097/QAD.0000000000000079. AIDS. 2014. PMID: 24413312 No abstract available.
References
-
- Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267–1274. - PubMed
-
- Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129. - PubMed
-
- Palella FJ, Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620–626. - PubMed
-
- Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis. 2003;188:1659–1665. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI035042/AI/NIAID NIH HHS/United States
- M01 RR000079/RR/NCRR NIH HHS/United States
- UO1-AI-34994/AI/NIAID NIH HHS/United States
- UO1-AI-34989/AI/NIAID NIH HHS/United States
- UO1-AI-35042/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- UO1-CH-32632/CH/OID CDC HHS/United States
- UO1-AI-35040/AI/NIAID NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- UO1-AI-35004/AI/NIAID NIH HHS/United States
- UM1 AI035043/AI/NIAID NIH HHS/United States
- UO1-AI-34993/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- MO1-RR-00079/RR/NCRR NIH HHS/United States
- UL1-RR025005/RR/NCRR NIH HHS/United States
- UO1-AI-35039/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- MO1-RR-00083/RR/NCRR NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- UO1-AI-35041/AI/NIAID NIH HHS/United States
- M01 RR000071/RR/NCRR NIH HHS/United States
- U01 AI035041/AI/NIAID NIH HHS/United States
- UM1-AI-35043/AI/NIAID NIH HHS/United States
- UO1-AI-42590/AI/NIAID NIH HHS/United States
- U01 AI035040/AI/NIAID NIH HHS/United States
- UO1-AI-31834/AI/NIAID NIH HHS/United States
- M01 RR000083/RR/NCRR NIH HHS/United States
- MO1-RR-00071/RR/NCRR NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
